Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Citi Likes CN Healthcare Sector; Top Picks WUXI APPTEC/ WUXI BIO
Recommend 25 Positive 20 Negative 14 |
||||
|
||||
|
Market interest in China's healthcare sector, particularly in innovative drugs, picked up strongly since April 2025, suggesting that the contract sales organization (CXO) sector will attract more attention ahead of the summer reporting season, with the leaders benefiting from improving fundamentals, attractive valuations and continued growth in order backlog, Citi Research issued a research report saying. The broker upgraded TIGERMED CONSULTING(300347.SZ)'s A-shares to Buy from Sell, as it believed that most of the leaders are trading at low prices. WUXI APPTEC (02359.HK) (603259.SH) and WUXI BIO (02269.HK) are its top picks. For WUXI XDC (02268.HK), faster growth in undelivered orders could boost its 1H25 revenue beyond guidance. As for TIGERMED CONSULTING, Citi Research upgraded its A-share to Buy, meanwhile keeping rating at Buy on TIGERMED (03347.HK). The broker also lifted its target prices to RMB67/ $73 from RMB34/ $37, respectively. The table below shows Citi Research's assessment on related pharmaceutical companies: Stock |Rating |TP APPTEC(603259.SH)|Buy| RMB88 WUXI BIO (02269.HK)|Buy|$35 TIGERMED (03347.HK)|Buy|$73 WUXI XDC (02268.HK)|Buy|$46 PHARMARON (03759.HK)|Buy|$33 AAStocks Financial News Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
